Skip to content

ExeVir Bio

Active
Private limited companyfounded 2020active for 6 yearsTechnologiepark-Zwijnaarde 94, 9052 Gent, BelgiumKBO/BCE: BE 0750.495.334
Summary

The annual accounts of ExeVir Bio for financial year 2025 show a net loss of 52% of total assets. The 2025 annual accounts show equity of €3.7m and a net result of -€1.9m. Equity is shrinking by about 36% per year and would, assuming unchanged policy, indicatively turn negative around financial year 2026. Its solvency ranks better than 95% of 271 sector peers (NACE 72, financial year 2025). The company has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.2% (very low).

Risk analysisFollow ReportCompare
ExeVir BioActiveChecked score 55/100
Risk analysis ReportCompare

Group and network

Connections & network

5 connected companies
Depth
Stef Heylen, Shared director, links 3 companies SHStef HeylenAlzheimer Liga Vlaanderen, via Stef Heylen ALAlzheimer LigaVlaanderenFEDERATION BELGE DES INDUSTRIES CHIMIQUES ET DES SCIENCES DE LA VIE, via Stef Heylen FBFEDERATIONBELGE DES…Janssen Pharmaceutica, via Stef Heylen JPJanssenPharmaceuticaVAN BIERVLIET Jérôme, Shared director VBVAN BIERVLIETJérômeTrim Therapeutics, via VAN BIERVLIET Jérôme TTTrimTherapeuticsLGP Advisory, Shared director LALGP AdvisoryExeVir Bio ExeVir Bio0750.495.334
Shared directors
This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.
Linked via shared directors
Alzheimer Liga Vlaanderen
via Stef Heylen · Director
→
Trim Therapeutics
via VAN BIERVLIET Jérôme · Director
→
FEDERATION BELGE DES INDUSTRIES CHIMIQUES ET DES SCIENCES DE LA VIE
via Stef Heylen · Director
former→
Janssen Pharmaceutica
via Stef Heylen · Managing director
former→
Show 1 more companies with a shared director
LGP Advisory
Shared director
→

We would like to set cookies. That happens only with your consent. What we measure